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fd. Note - This overview was originally presented at the 
International Symposium on Clinical Disorders of Bone 
and Mineral Metabolism, May 9-13,1983. The following 
list indicates the presentations given in this session at the 
Symposium and the contents ofthe corresponding chap-
ter in the Proceedings of the Symposium published by 
Excerpta Medica. The numbers in parentheses refer to 
pages in this volume. Complete information about the 
contents ofthe Proceedings can be found at the back of 
this issue. 
Vitamin D metabolities: New physiologic and clinical 
insights. M.R. Haussler, S. Dokoh, D.J. Mangelsdorf, C A . 
Donaldson, and J.W. Pike (68) 
Vitamin D metabolism in man: Contributions from cl ini-
cal studies. S.W. Stanbury and E.B. Mawer (72) 
The cardinal role of1,25-dihydroxyvitamin D y n mineral 
homeostasis. H.F. DeLuca (78) 
The role of 1,25{OH)yD^ in the pathogenesis of osteo-
malacia. H. Rasmussen (82) 
W i t h t h e availability of stereospecific assays for vitamin 
D and its metabolites, many clinicians now measure 
these sterols in evaluating the pathogenesis and treat-
ment of diseases affecting mineral and skeletal homeo-
stasis. Since some of these assays are commercially avail-
able, it seems appropriate to reflect on what they 
measure and how to interpret the results. Much new 
information published over the past 10-12 years can be 
confusing. Other sections of this Symposium dealt spe-
cifically with certain diseases affecting vitamin D metab-
olism, but Haussler, Stanbury, DeLuca, and Rasmussen 
dealt directly with the biological relevance of sterol pro-
duct ion, quantitat ion, and the interpretation of the 
sterol assay data in light o f the presumed activities of the 
vitamin's metabolites. 
As indicated by Haussler and colleagues (pp. 68 ff.), the 
competit ive protein binding assays (CPBA) have had the 
greatest usage, but we must be aware of the improved 
technology suggested by the novel cytoreceptor assay 
(1), polyclonal radioimmunoassay (RIA) (2), monoclonal 
RIA (3), and innovative, facile preparative approaches to 
CPBA (4). Continuing progress in the development of 
selective, sensitive, precise, convenient assays seems 
likely. Although available, quantitation of the vitamin D 
carrier protein (DBP) has not gained wide usage in the 
interpretation of " b o u n d " or " f r e e " sterol (5). I f the role 
of DBP in blood sterol transport is indeed passive and not 
one of carrier-mediation into tissues, it seems likely that 
estimates of " f r ee " sterol could be useful in situations in 
which sterol transport is either compromised or aug-
mented by changes in the protein's concentration and/or 
its occupancy by sterols. 
Two controversial areas in the interpretation of sterol 
values are the role(s) of sterols other than 1,25-(OH)2D 
and the relevance of the extrarenal production of 1,25-
(OH)2D. These areas were directly addressed in this sec-
t ion. The emphasis of Stanbury and Mawer (pp. 72 ff.) on 
1,25-(OH)2D underscored the view that this sterol is the 
cardinal metabolite in the expression of the vitamin's 
" t radi t ional" biological activity. The clear-cut alliances of 
several relevant diseases with 1,25-(OH)2D underproduc-
t ion, overproduction, and resistance support this posi-
t ion. Extrarenal 1,25-(OH)2D synthesis currently appears 
to be clinically significant in sarcoidosis and certainly of 
interest in pregnancy, but as DeLuca (pp. 78 ff.) indicated, 
of uncertain in vivo significance in other tissues. 
Rasmussen (pp. 82 ff.) provided a broad view of sterol 
action and addressed the controversial areas dealing with 
the role of other sterols in mineral and skeletal homeosta-
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tis. in contrast to Rasmussen's content ion, DeLuca indi-
cated that the introduction of a f luoro group at position 
C-25 markedly reduced biological activity, but that a 
f luoro group at C-24 did not reduce biological effects. 
The concept of both renal and extrarenal biosynthesis of 
1,25-(OH)2D has withstood challenges far better than 
hypotheses of new target tissues for this potent sterol. 
Many reports have convincingly demonstrated the pres-
ence of high affinity, selective 1,25-(OH)2D receptors in 
tissues not usually associated with major translocations 
of mineral ions (6). This latter review also suggested a 
role for 24,25-(OH)2D in various activities, but Haussler 
and co-workers revealed their present inability to con-
f i rm these findings. An exciting development by Pike (7) 
is the production of monoclonal antibodies to the 1,25-
(OH)2D receptor, which provides a new probe to reveal 
the topography and relevance of the sterol-receptor 
association. The influence of 1,25-(OH)2D on cellular 
dif ferentiat ion, whether calcium-mediated or not, will 
clearly attract future investigators. 
The influencesof 1,25-(OH)2Don cel lulardif ferentiat ion 
provide some basis to broaden our viewpoints about the 
action(s) and target tissues for vitamin D. This area, in 
relationship to myelogenous leukemia cells, has recently 
been reviewed (8). Further work may be expected in the 
delineation of sterol effects on cells not classically asso-
ciated with bulk transfer of minerals. 
Interesting clinical observations by Stanbury and Mawer 
suggested the importance of several factors in carefully 
interpreting sterol assay values. Nutrit ional or photobio-
logical, hormonal, and possibly ionic and autoregulatory 
influences can condit ion blood sterol concentration. 
Recent studies of the clearance of sterol(s) f rom blood 
suggest that alterations in sterol degradation might char-
acterize certain conditions, such as the augmented loss 
of water-soluble sterol conjugates into the urine of 
patients with cholestatic liver disease (9). 
The relationships among 1,25-(OH)2D and substrate sterol, 
ions, and hormones addressed by Stanbury and Mawer 
underscored their importance in the interpretation of 
single and perturbed plasma 1,25-(OH)2D levels. Provoc-
ative testing of 25-OHD-1a-hydroxylase activity will 
clearly be an active area for future workers (10). 
A major clinical focus for the controversy surrounding 
the importance of 1,25-(OH)2D is the observation that 
osteomalacia can develop in the presence of slightly 
high, normal, or low blood concentrations of this sterol. 
Several factors are relevant: substrate (25-OHD) availa-
bility, dietary mineral content, age of the patient or rate 
of growth, degree of secondary hyperparathyroidism, 
renal funct ion. In other words, normal 1,25-(OH)2D 
blood levels may be inappropriately low in a situation 
demanding very high levels in order to provide sufficient 
intestinal mineral transportfor mineralization of theske-
leton. The observation that 1,25-(OH)2D blood levels are 
five to six times higher during the healing of vitamin 
D-deficient osteomalacia suggests the possibility of a 
non-PTH, la-hydroxylase-stimulator of skeletal origin. 
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